

FOR IMMEDIATE RELEASE

VMRD Releases New Feline Test for the Biomarker Serum Amyloid A (SAA)

PULLMAN, WA, MARCH 01, 2022--VMRD, a leading veterinary diagnostics manufacturer, is pleased to announce the release of their new test, VMRD SAA for Feline.

“In recent years, SAA has been used extensively by equine veterinarians with great success to help diagnose infection and monitor treatment efficacy,” says Veterinary Affairs Manager Siddra Hines, DVM, PhD, DACVIM. “Following the release of VMRD SAA for Equine in 2019, we realized there was an unmet need for such a valuable tool in feline medicine as well.”

SAA is an inflammatory biomarker that increases rapidly and dramatically with most infections, which can be particularly challenging to diagnose in cats. It is often more sensitive than fever or white blood cell count for detecting subclinical infections and decreases rapidly when effective treatment is instituted.

“Cats are very stoic creatures, and often do not show signs of serious illness until the situation is critical,” states Chief Scientific Officer Don Knowles, DVM, PhD, DACVP. “Now VMRD SAA for Feline can help companion animal veterinarians identify infections early and objectively monitor clinical condition in cats.”

VMRD SAA for Feline is a 10-minute test that can be run in-clinic on a handheld reader, which provides numerical results for easy interpretation.

For more information on VMRD point-of-care products, including the VMRD SAA test for Feline, please visit our website at vmrd.com/poc or contact us at vets@vmrd.com.

-end-